vs
Amphastar Pharmaceuticals, Inc.（AMPH）与NATIONAL BEVERAGE CORP（FIZZ）财务数据对比。点击上方公司名可切换其他公司
NATIONAL BEVERAGE CORP的季度营收约是Amphastar Pharmaceuticals, Inc.的1.6倍（$288.3M vs $183.1M），NATIONAL BEVERAGE CORP净利率更高（16.1% vs 13.3%，领先2.7%），NATIONAL BEVERAGE CORP同比增速更快（-1.0% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $19.9M），过去两年NATIONAL BEVERAGE CORP的营收复合增速更高（3.3% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
国家饮料公司是美国的饮料开发、生产及分销企业，总部位于佛罗里达州劳德代尔堡，主打风味软饮产品，旗下知名品牌包括LaCroix气泡水、Shasta和Faygo等，产品覆盖美国多地消费市场。
AMPH vs FIZZ — 直观对比
营收规模更大
FIZZ
是对方的1.6倍
$183.1M
营收增速更快
FIZZ
高出0.8%
-1.8%
净利率更高
FIZZ
高出2.7%
13.3%
自由现金流更多
AMPH
多$4.7M
$19.9M
两年增速更快
FIZZ
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $288.3M |
| 净利润 | $24.4M | $46.4M |
| 毛利率 | 46.8% | 37.9% |
| 营业利润率 | 19.4% | 20.1% |
| 净利率 | 13.3% | 16.1% |
| 营收同比 | -1.8% | -1.0% |
| 净利润同比 | -35.7% | 1.6% |
| 每股收益（稀释后） | $0.51 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHFIZZ
| Q4 25 | $183.1M | $288.3M | ||
| Q3 25 | $191.8M | $330.5M | ||
| Q2 25 | $174.4M | $313.6M | ||
| Q1 25 | $170.5M | $267.1M | ||
| Q4 24 | $186.5M | $291.2M | ||
| Q3 24 | $191.2M | $329.5M | ||
| Q2 24 | $182.4M | $297.3M | ||
| Q1 24 | $171.8M | $270.1M |
净利润AMPHFIZZ
| Q4 25 | $24.4M | $46.4M | ||
| Q3 25 | $17.4M | $55.8M | ||
| Q2 25 | $31.0M | $44.8M | ||
| Q1 25 | $25.3M | $39.6M | ||
| Q4 24 | $38.0M | $45.6M | ||
| Q3 24 | $40.4M | $56.8M | ||
| Q2 24 | $37.9M | $43.7M | ||
| Q1 24 | $43.2M | $39.6M |
毛利率AMPHFIZZ
| Q4 25 | 46.8% | 37.9% | ||
| Q3 25 | 51.4% | 38.0% | ||
| Q2 25 | 49.6% | 36.1% | ||
| Q1 25 | 50.0% | 37.1% | ||
| Q4 24 | 46.5% | 37.6% | ||
| Q3 24 | 53.3% | 37.2% | ||
| Q2 24 | 52.2% | 36.7% | ||
| Q1 24 | 52.4% | 35.9% |
营业利润率AMPHFIZZ
| Q4 25 | 19.4% | 20.1% | ||
| Q3 25 | 13.2% | 21.4% | ||
| Q2 25 | 24.2% | 18.3% | ||
| Q1 25 | 21.9% | 18.9% | ||
| Q4 24 | 24.2% | 19.9% | ||
| Q3 24 | 29.8% | 21.1% | ||
| Q2 24 | 30.3% | 17.8% | ||
| Q1 24 | 27.9% | 17.8% |
净利率AMPHFIZZ
| Q4 25 | 13.3% | 16.1% | ||
| Q3 25 | 9.0% | 16.9% | ||
| Q2 25 | 17.8% | 14.3% | ||
| Q1 25 | 14.8% | 14.8% | ||
| Q4 24 | 20.4% | 15.7% | ||
| Q3 24 | 21.1% | 17.2% | ||
| Q2 24 | 20.8% | 14.7% | ||
| Q1 24 | 25.1% | 14.7% |
每股收益（稀释后）AMPHFIZZ
| Q4 25 | $0.51 | $0.49 | ||
| Q3 25 | $0.37 | $0.60 | ||
| Q2 25 | $0.64 | $0.47 | ||
| Q1 25 | $0.51 | $0.42 | ||
| Q4 24 | $0.74 | $0.49 | ||
| Q3 24 | $0.78 | $0.61 | ||
| Q2 24 | $0.73 | $-52.00 | ||
| Q1 24 | $0.81 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $269.3M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $551.3M |
| 总资产 | $1.6B | $749.0M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHFIZZ
| Q4 25 | $282.8M | $269.3M | ||
| Q3 25 | $276.2M | $249.8M | ||
| Q2 25 | $231.8M | $193.8M | ||
| Q1 25 | $236.9M | $149.2M | ||
| Q4 24 | $221.6M | $112.8M | ||
| Q3 24 | $250.5M | $77.0M | ||
| Q2 24 | $217.8M | $327.0M | ||
| Q1 24 | $289.6M | $277.0M |
总债务AMPHFIZZ
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHFIZZ
| Q4 25 | $788.8M | $551.3M | ||
| Q3 25 | $776.7M | $504.1M | ||
| Q2 25 | $757.5M | $444.0M | ||
| Q1 25 | $751.3M | $400.2M | ||
| Q4 24 | $732.3M | $360.1M | ||
| Q3 24 | $727.7M | $306.6M | ||
| Q2 24 | $713.3M | $559.5M | ||
| Q1 24 | $672.4M | $510.2M |
总资产AMPHFIZZ
| Q4 25 | $1.6B | $749.0M | ||
| Q3 25 | $1.7B | $737.8M | ||
| Q2 25 | $1.6B | $672.9M | ||
| Q1 25 | $1.6B | $594.0M | ||
| Q4 24 | $1.6B | $557.4M | ||
| Q3 24 | $1.5B | $522.6M | ||
| Q2 24 | $1.5B | $770.2M | ||
| Q1 24 | $1.6B | $719.9M |
负债/权益比AMPHFIZZ
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $19.9M |
| 自由现金流率自由现金流/营收 | 13.4% | 6.9% |
| 资本支出强度资本支出/营收 | 4.5% | 2.0% |
| 现金转化率经营现金流/净利润 | 1.35× | 0.55× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $156.8M |
8季度趋势，按日历期对齐
经营现金流AMPHFIZZ
| Q4 25 | $32.9M | $25.7M | ||
| Q3 25 | $52.6M | $59.1M | ||
| Q2 25 | $35.6M | $60.1M | ||
| Q1 25 | $35.1M | $46.5M | ||
| Q4 24 | $29.0M | $42.6M | ||
| Q3 24 | $60.0M | $57.5M | ||
| Q2 24 | $69.1M | $60.4M | ||
| Q1 24 | $55.3M | $35.4M |
自由现金流AMPHFIZZ
| Q4 25 | $24.6M | $19.9M | ||
| Q3 25 | $47.2M | $56.0M | ||
| Q2 25 | $25.0M | $44.6M | ||
| Q1 25 | $24.4M | $36.3M | ||
| Q4 24 | $16.6M | $35.7M | ||
| Q3 24 | $46.2M | $53.8M | ||
| Q2 24 | $63.1M | $49.6M | ||
| Q1 24 | $46.5M | $28.7M |
自由现金流率AMPHFIZZ
| Q4 25 | 13.4% | 6.9% | ||
| Q3 25 | 24.6% | 16.9% | ||
| Q2 25 | 14.3% | 14.2% | ||
| Q1 25 | 14.3% | 13.6% | ||
| Q4 24 | 8.9% | 12.3% | ||
| Q3 24 | 24.1% | 16.3% | ||
| Q2 24 | 34.6% | 16.7% | ||
| Q1 24 | 27.1% | 10.6% |
资本支出强度AMPHFIZZ
| Q4 25 | 4.5% | 2.0% | ||
| Q3 25 | 2.8% | 0.9% | ||
| Q2 25 | 6.1% | 4.9% | ||
| Q1 25 | 6.3% | 3.8% | ||
| Q4 24 | 6.7% | 2.4% | ||
| Q3 24 | 7.2% | 1.1% | ||
| Q2 24 | 3.3% | 3.6% | ||
| Q1 24 | 5.1% | 2.5% |
现金转化率AMPHFIZZ
| Q4 25 | 1.35× | 0.55× | ||
| Q3 25 | 3.03× | 1.06× | ||
| Q2 25 | 1.15× | 1.34× | ||
| Q1 25 | 1.39× | 1.17× | ||
| Q4 24 | 0.76× | 0.93× | ||
| Q3 24 | 1.48× | 1.01× | ||
| Q2 24 | 1.82× | 1.38× | ||
| Q1 24 | 1.28× | 0.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
FIZZ
暂无分部数据
